Translational Development Acquisition Corp. cash flow to debt ratio of -304.19% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Translational Development Acquisition Corp.'s free cash flow has increased 28.55% from $-851.45K last year to $-608.39K, signaling increasing performance

Translational Development Acquisition Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Translational Development Acquisition Corp.'s debt has decreased relative to shareholder equity from 36.21K last year to 0.00 today, signaling strengthened financials

Translational Development Acquisition Corp. has negative EBITDA, making leverage ratio unreliable

Interest expense is not separately reported in Translational Development Acquisition Corp.'s latest filing, so interest coverage cannot be calculated.

Translational Development Acquisition Corp.'s profit margin has increased (100.00%) in the last year from -6.66% to 0.00%, signaling increasing performance

Translational Development Acquisition Corp.'s short-term liabilities of $544.07K exceed its short-term assets of $39.47K, signaling financial risk

Translational Development Acquisition Corp.'s return on assets of 3.52% is lower than the 5.00% threshold, indicating inefficient asset utilization

Translational Development Acquisition Corp.'s return on equity of 3.28%, is lower than 15.00%, indicating bad performance

Translational Development Acquisition Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Translational Development Acquisition Corp. has insufficient public price history to evaluate earnings stability.

Translational Development Acquisition Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Translational Development Acquisition Corp. has negative free cash flow, indicating cash burn

Translational Development Acquisition Corp.'s yearly earnings has increased 9.06K% since last year from $-71.01K to $6.36M, signaling increasing performance

Translational Development Acquisition Corp.'s yearly revenue has decreased 100.00% since last year from $1.07T to $0.00, signaling decreasing performance

ROIC -0.84% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Translational Development Acquisition Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

Translational Development Acquisition Corp. has insufficient public price history to evaluate revenue consistency.

Translational Development Acquisition Corp. has insufficient public price history to evaluate ROE consistency.

Translational Development Acquisition Corp. has insufficient data to evaluate this check.

Translational Development Acquisition Corp. has an earnings yield of 3.03%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Translational Development Acquisition Corp. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Translational Development Acquisition Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Translational Development Acquisition Corp. has insufficient data to evaluate this check.

Translational Development Acquisition Corp. has insufficient diluted EPS history to calculate the PEG ratio.

Translational Development Acquisition Corp. has a price-to-book ratio of 1.22x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Translational Development Acquisition Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue